SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Ra Medical Systems, Inc. RMED NYSE

NYSE • Healthcare • Medical - Devices • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Ra Medical Systems, Inc. (RMED) is a Medical - Devices company in the Healthcare sector, currently trading at $0.59. It has a SharesGrow Score of 30/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Financials: revenue is $819,000, +986.2%/yr average growth. Net income is $17M (loss), growing at +13.8%/yr. Net profit margin is -2098% (negative). Gross margin is 92.3% (+7083.2 pp trend).

Balance sheet: total debt is $4M against $7M equity (Debt-to-Equity (D/E) ratio 0.55, moderate). Current ratio is 0.1 (tight liquidity). Debt-to-assets is 24.2%. Total assets: $16M.

Analyst outlook: 2 / 5 analysts rate RMED as buy (40%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 90/100 (Pass), Past 0/100 (Fail), Health 17/100 (Fail), Moat 50/100 (Partial), Future 20/100 (Fail), Income 10/100 (Fail).

RMED SharesGrow Score Overview

37/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 90/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 17/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 50/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — RMED

No analyst coverage available for this stock.

RMED: +986.2%/yr revenue is, +13.8%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet RMED: Debt-to-Equity (D/E) ratio 0.55 (moderate), Current ratio is 0.1 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

RMED: Gross margin is 92.3% (+7083.2 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 5 analysts rate RMED as buy (40%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

RMED: Net profit margin is -2098%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.4808-11.135

Volume74.5K

Avg Volume (30D)290.93K

Market Cap$3.84M

Beta (1Y)0.00

Share Statistics

EPS (TTM)-15.90

Shares Outstanding$1.08B

IPO Date2018-09-27

Employees14

CEODavid A. Jenkins

Financial Highlights & Ratios

Revenue (TTM)$819K

Gross Profit$756K

EBITDA$-21.08M

Net Income$-17.18M

Operating Income$-21.08M

Total Cash$88K

Total Debt$3.85M

Net Debt$3.76M

Total Assets$15.86M

Price / Earnings (P/E)-0

Price / Sales (P/S)4.69

Analyst Forecast

Rating ConsensusHold

Analysts Covering5

Buy 40% Hold 60% Sell 0%

Company Info

CountryUS

ExchangeNYSE

CurrencyUSD

ISINUS74933X1046

Price Chart

RMED

Ra Medical Systems, Inc. ↗ · NYSE

Healthcare • Medical - Devices

0.48 52WK RANGE 11.14

People Also View

IRIDEX Corporation

Sintx Technologies, Inc.

Tenon Medical, Inc.

Talis Biomedical Corporation

Heart Test Laboratories, Inc.

INVO Bioscience, Inc.

ReShape Lifesciences Inc.

Bone Biologics Corporation

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message